HUE030946T2 - Tienopiridon-származékok AMPK-aktivátorokként való alkalmazásra - Google Patents

Tienopiridon-származékok AMPK-aktivátorokként való alkalmazásra Download PDF

Info

Publication number
HUE030946T2
HUE030946T2 HUE13732533A HUE13732533A HUE030946T2 HU E030946 T2 HUE030946 T2 HU E030946T2 HU E13732533 A HUE13732533 A HU E13732533A HU E13732533 A HUE13732533 A HU E13732533A HU E030946 T2 HUE030946 T2 HU E030946T2
Authority
HU
Hungary
Prior art keywords
chloro
hydroxy
groups
thieno
pyridin
Prior art date
Application number
HUE13732533A
Other languages
English (en)
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Sebastien Bolze
Franck Lepifre
Laurent Faveriel
Jean-Denis Durand
Christine Charon
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of HUE030946T2 publication Critical patent/HUE030946T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (2)

  1. GYaMÖMldl igény pontok
    1. £gy képletü vegyülni, azzal jellemezve, hogy. Rí jelentése hidrogénatom vagy halogénatom; R2 jelentése Incianll· vagy tetfanlbesoport, amely szubsztituált vagy nem egy vagy tóbh, a hsiogenatornok. alkjlmsoportök, hidroxK ilkcxi-csoportok, amino~, metio» vagy dialkíl-amino-csoportök, karboxncsoporfok. alkil-oKl-karhonii-csoportok, mono-vagy diaikii-aminö-karbon^csoportök, karboxamid-, eiane-, atkli-szulfonN- ès a trifluor-metil -csoportok közül kiválasztott csoporttal; R3 jelentése ant· vagy heteroarii-csopoit amely mgy-mm egy vagy több; a halogénaiornok. aikií-esoporíúk, hidroxl·. alkoxi-csoportok, araikíl-oxi-csoportoK, amino-, mono- vagy dlalkli-arnino -csoportok, karboxi-osoportok, alkil-oxi-karbonit-csoportokmono- vagy dialkikamlno- kafbonil-csoportok. karboxamid-. ciano-, aíkil-szuífonií- es a tntluor-metfi-esoportok közül IPvalaszíoti atommal vagy csoporttal; vagy ennek egy geometriai ízornerje, tautomene. eplrnerje, enantiomerje, sztereolzo-rnerje diasztereorzorone racernátja, ezek gyógyszorészetileg elfogadható sója vagy szoivátja, amelyet a. 2-klór~4-hidroxí--3anöan-5'íl-5“fenil-7H-íie?io[2.3-bJpiridín-8-on 2-klör-5-(44luor-fe- nil)-4~hidroxi •sI-maam-ö-'N-vB-temojy.3-b]pindin-6-on 2-klór-4 - h ;drοχ I-3 -1ndarvö-k-S·-(3YTieiox;4ervi}--7H4lerv::y;G3--b]piridln-'B-on 2-kiór-4-hidrovl-3-indafv5-il-6-(4vmet-oxi-feni!}-7H--tleno[2>3-bjpirldln-6-on 3'(2-klôr--4-hïdroxi-3-indan--5-d-6-ôxo-'7H--tie·· noî,2.P--bjpindin-5-k}benzorNtrH 2''k;ór-4.-hldroxr-3'»Klan-5GI-4-21-01031-18011)--711-118-no|2t3-bjpiridin-6-on 2--kior-5'-(43iuor-ferd:)--4-'hk.lrox;'-3--(4-hidroki--indan-5-äii--7H--tse-' nof^^-bjpsrioin-b-on 2-kior-0“{3"fiuor-fensl)-4"hjdroxj-3-{4~hidroxs-lndan-5~H)-7H-t!e-r;o[2;3-bjpindin-6-on 2-Κ?0Γ·4-Η1ΡΓθχΙ-3··ίί^οη-δ-ϋ-δ-(3··ρΐ^ΙΙ)-71·«ίθηο|[2.3·5]ρΐΓκϋη·· Son 2 -kJô r-4" h id ητχΡ 3- (4 '4·; I d m x h n d a n - 5 3 i V- S --fe rs i I - 7 H -Ί ie η ο Í 2,3 -b |pi nőin -6 - or; 2-kíór-5"{2"fiuor-feníi)~4“hiciro>:i-3“{4-hfdi'oxi-imjan'5"l!)“?H'tienoj'2!3''b]pírkÍÍn~6"On 2-klôr-4"hidroxi''3"(6''hielroxi-{etraiin-'8-il}-5-Îeni!-7H-ffeno{2.3-b]pinclin"6-on 3-<2-klôr- 4- hidr0xnS"OXo~3-teiraHn~S“H“?B-lieno[z.3~b}pindin-6--irrhenzonitni ?.-kiôr-4-hkJfDXi- 5- (3-pifidii}-34etralin~S~il'7H-tieno[2.3m]piridin~8-on trinálrium~2-klőr-3-{5>óxidö4et·' ralin«8«il)~5«fenii-tienof2>3-b]piridin*4.e*diolât 2-klóM«hidroxi^fenii-3-feiraiin-6<il· /H-îseno[2,3"b)plr5din-6~on 2'kíór-5"{4-fsuor4enilH''hidroxi“3"{5'-hidroxi'-tefra!in-6-'iO~ rH-tieno^S-hlpindin-S-on dinátriürn-2'kiár-3“($-axídö~tetrali?vS"ií}-6-oxo-5"fenil· /H~t!enoi2:3~b)p!ndín-4--oieát 2-k!ór-4"hidröxj-3-{5"hídröxi-feiraíin-8-ii}-5~(3-rneííl-feni;)-7H-imnot3,3m)pindm-6-on 2-k!6r~4midroxb3-{5~hidroxi”ietr3lin-6-ilK5'(4-me-iil-fenil)-?H*tienof2(3»b)pinclin-6-ori 2-kiór~5~f3'fluor-feníi)-4-hidroxí-3-f5''nidrox!~tet-: rahn3S3i)'?H4ieno[23bb]piridin-'8'ün nátrjum“2“klör»3”(5-hidroxMetrafin-6~)3}"8'Oxo·· 5'fe?iil~?H-tieno(2.3«b|pin<lin<4-Qleái káíium-2-kiór-3-{5-hidraxi-tefralin>84!}*6»oxo-5*> íénii-7H-tieno[2 ; 3~bjpsridin-4-oleat által alkotott csoportból választunk Ki.
  2. 2, Gyógyszerkészítmény. amely tartalmaz az 1. Igénypont szerinti yégyCttétik közül legalább agyét, valamint egy gyégyszerészetlíeg elfogadható hordozót egy 1. Igénypont szerinti vegyülni diabétesz, metaholíkus senorom a. alhl-zoítság. màjbetegsèg, hepatikus szteatózls, nem-alkoholos zsíros máj betegség íNAFLUí, nem-alkoholos szteato-hepatltisz. (NASH), májftbrózis. diszlipidémla. hlper-togücendémsa, hspeikolesztennémia. gyulladás, rák. szív-érrendszeri betegségek, ateroszkierozis, magas vérnyomás, retinopáíiik és neuropátlák kezelésében való alkalmazásra.
HUE13732533A 2012-06-29 2013-06-28 Tienopiridon-származékok AMPK-aktivátorokként való alkalmazásra HUE030946T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305775.4A EP2679591A1 (en) 2012-06-29 2012-06-29 Thienopyridone derivatives useful as activators of AMPK

Publications (1)

Publication Number Publication Date
HUE030946T2 true HUE030946T2 (hu) 2017-06-28

Family

ID=48703549

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13732533A HUE030946T2 (hu) 2012-06-29 2013-06-28 Tienopiridon-származékok AMPK-aktivátorokként való alkalmazásra

Country Status (26)

Country Link
US (1) US9284329B2 (hu)
EP (2) EP2679591A1 (hu)
JP (1) JP5972460B2 (hu)
KR (1) KR101704448B1 (hu)
CN (2) CN104395319B (hu)
AU (1) AU2013283239B2 (hu)
BR (1) BR112014032526B1 (hu)
CA (1) CA2876789C (hu)
CY (1) CY1118213T1 (hu)
DK (1) DK2867240T3 (hu)
EA (1) EA026300B1 (hu)
ES (1) ES2603737T3 (hu)
HR (1) HRP20161482T1 (hu)
HU (1) HUE030946T2 (hu)
IL (1) IL236221A (hu)
IN (1) IN2014MN02661A (hu)
LT (1) LT2867240T (hu)
ME (1) ME02537B (hu)
MX (1) MX359221B (hu)
PL (1) PL2867240T3 (hu)
PT (1) PT2867240T (hu)
RS (1) RS55308B1 (hu)
SI (1) SI2867240T1 (hu)
SM (1) SMT201600418B (hu)
WO (1) WO2014001554A1 (hu)
ZA (1) ZA201500593B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105078992B (zh) * 2014-05-23 2017-11-21 资元堂生物科技股份有限公司 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104910129A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 含六甲基苯环和卤代苯结构的黄原酸酯类化合物、其制备方法及用途
CN104910130A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和氨基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105541715B (zh) * 2016-02-02 2019-04-09 浙江工业大学 多取代吡啶-1(2h)-酮衍生物及其合成方法与应用
KR101925020B1 (ko) 2017-04-21 2018-12-04 연세대학교 산학협력단 Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물
SG11202006723SA (en) * 2018-02-08 2020-08-28 Enyo Pharma Non-fused thiophene derivatives and their uses
CN108516972A (zh) * 2018-05-30 2018-09-11 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
MX2021005772A (es) * 2018-11-16 2021-10-13 Poxel Sal de monohidrato potasico de un derivado de tienopiridona y su proceso de preparacion.
US20220184172A1 (en) * 2019-04-19 2022-06-16 The Regents Of The University Of California Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
WO2021037702A1 (en) 2019-08-28 2021-03-04 Poxel Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases
WO2021105075A1 (en) * 2019-11-27 2021-06-03 Société des Produits Nestlé S.A. Dibenzopyran ampk activator compounds, compositions, methods and uses thereof
EP4125886A1 (en) 2020-03-26 2023-02-08 Poxel Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy
WO2021198284A1 (en) 2020-03-30 2021-10-07 Poxel Use of a thienopyridone derivative in the treatment of cardiovascular diseases
US20230149370A1 (en) 2020-03-30 2023-05-18 Poxel Use of a thienopyridone derivative in the treatment of diabetic nephropathy
DK4125887T3 (da) * 2020-04-02 2024-05-06 Poxel Anvendelse af et thienopyridonderivat til behandling af en autosomal dominant polycystisk nyresygdom (adpkd)
WO2021204755A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
WO2021204751A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
DK2262500T3 (en) 2008-04-11 2016-08-15 Merck Patent Gmbh THIENOPYRIDON DERIVATIVES AS AMP-ACTIVATED PROTEINKINASE (AMPK) ACTIVATORS
MY160357A (en) * 2008-05-05 2017-02-28 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Also Published As

Publication number Publication date
CA2876789C (en) 2017-01-31
IN2014MN02661A (hu) 2015-08-28
BR112014032526B1 (pt) 2022-11-01
HRP20161482T1 (hr) 2016-12-30
JP5972460B2 (ja) 2016-08-17
SMT201600418B (it) 2017-01-10
MX359221B (es) 2018-09-18
AU2013283239A1 (en) 2015-01-22
CY1118213T1 (el) 2017-06-28
US20150166566A1 (en) 2015-06-18
CN104395319B (zh) 2017-10-27
EP2679591A1 (en) 2014-01-01
JP2015521651A (ja) 2015-07-30
US9284329B2 (en) 2016-03-15
IL236221A0 (en) 2015-02-01
CA2876789A1 (en) 2014-01-03
EA201500064A1 (ru) 2015-08-31
ES2603737T3 (es) 2017-03-01
ZA201500593B (en) 2016-01-27
EP2867240A1 (en) 2015-05-06
IL236221A (en) 2017-12-31
EP2867240B1 (en) 2016-09-14
LT2867240T (lt) 2016-12-27
RS55308B1 (sr) 2017-03-31
CN104395319A (zh) 2015-03-04
SI2867240T1 (sl) 2017-01-31
KR20150033709A (ko) 2015-04-01
KR101704448B1 (ko) 2017-02-08
CN107266467A (zh) 2017-10-20
DK2867240T3 (en) 2016-12-05
ME02537B (me) 2017-02-20
PT2867240T (pt) 2016-11-24
WO2014001554A1 (en) 2014-01-03
BR112014032526A2 (pt) 2017-06-27
AU2013283239B2 (en) 2016-01-28
MX2014016107A (es) 2015-11-16
PL2867240T3 (pl) 2017-02-28
EA026300B1 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
EP2867240B1 (en) Thienopyridone derivatives useful as activators of ampk
EP2519527B1 (en) Thieno[2,3-b]pyridinedione activators of ampk and therapeutic uses thereof
US8563729B2 (en) Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
AU2009243811B2 (en) Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
ES2436195T3 (es) Derivados de la quinoxalinadiona
US6083952A (en) Compounds